Skip to main
GOVX

Geovax Labs (GOVX) Stock Forecast & Price Target

Geovax Labs (GOVX) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Geovax Labs Inc. is advancing its product pipeline with promising developments in both infectious disease vaccines and cancer immunotherapies, particularly through its next-generation COVID-19 vaccine, GEO-CM04S1, which has shown positive Phase 2 results in immunocompromised populations. The company benefits from favorable regulatory feedback for its Mpox/Smallpox vaccine and is utilizing a scalable manufacturing platform that addresses previous supply constraints, bolstering its growth potential. Additionally, strategic collaborations and ongoing assessment of gene-directed therapies, in conjunction with major health institutions, highlight Geovax's commitment to expanding its oncology initiatives, strengthening investor confidence in its long-term viability and market position.

Bears say

Geovax Labs faces significant financial challenges, notably a limited cash runway of $5 million at the end of Q3, coupled with high cash burn rates due to ongoing research and development activities. These conditions heighten the execution risk for the company, especially in a funding environment where nearly 40% of public biotechs are projected to exhaust their cash within the next year. Additionally, the elevated risks associated with financing and the depressed share price have led to a reassessment of the company's valuation, lowering it from $9.00 to $6.00 to account for potential dilution and funding uncertainties.

Geovax Labs (GOVX) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Geovax Labs and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Geovax Labs (GOVX) Forecast

Analysts have given Geovax Labs (GOVX) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Geovax Labs (GOVX) has a Strong Buy consensus rating as of Jan 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Geovax Labs (GOVX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.